rhTSH can be used, instead of withdrawal of thyroid hormone, for patients who have undergone total or near total thyroidectomy to investigate the presence of the remnant thyroid, recurrence, and metastatic lesions. rhTSH is considered very beneficial because it has diagnostic ability equal to the conventional method, does not damage QOL due to hypothyroidism, and can reduce the dose of exposure.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Mazzaferri EL, Robbins RJ, Spencer CA et al (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441 (SR<RS>)PubMedCrossRefGoogle Scholar
Eustatia-Rutten CF, Smit JW, Romijn JA et al (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 61:61–74 (SR<PS>)CrossRefGoogle Scholar
Taïeb D, Sebag F, Cherenko M et al (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol 71:115–123 (RCT)CrossRefGoogle Scholar
Pacini F, Ladenson PW, Schlumberger M et al (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932 (RCT)PubMedCrossRefGoogle Scholar
Hoftijzer HC, Bax JJ, Heemstra KA et al (2009) Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma. Eur J Clin Invest 39:204–210 (PS)PubMedCrossRefGoogle Scholar
Botella-Carretero JI, Galán JM, Caballero C et al (2003) Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 10:601–610 (PS)PubMedCrossRefGoogle Scholar
Botella-Carretero JI, Gómez-Bueno M, Barrios V et al (2004) Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 11:345–356 (PS)PubMedCrossRefGoogle Scholar
Karanikas G, Schütz M, Szabo M et al (2004) Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol 24:41–45 (PS)PubMedCrossRefGoogle Scholar
Münte TF, Lill C, Otting G et al (2004) Cognitive changes in short-term hypothyroidism assessed with event-related brain potentials. Psychoneuroendocrinology 29:1109–1118 (PS)PubMedCrossRefGoogle Scholar
Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803 (Others)PubMedCrossRefGoogle Scholar
Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673 (RS)PubMedCrossRefGoogle Scholar
Sorvillo F, Mazziotti G, Carbone A et al (2003) Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 88:4818–4822 (PS)PubMedCrossRefGoogle Scholar
Tuttle RM, Fleisher M, Francis GL et al (2002) Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737–1742 (RS)PubMedCrossRefGoogle Scholar
Sisson JC, Shulkin BL, Lawson S (2003) Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. J Nucl Med 44:898–903 (RS)PubMedGoogle Scholar
Hänscheid H, Lassmann M, Luster M et al (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648–654 (PS)PubMedGoogle Scholar
Haugen BR, Pacini F, Reiners C et al (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877–3885 (RCT)PubMedCrossRefGoogle Scholar
Pilli T, Brianzoni E, Capoccetti F et al (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546 (RCT)PubMedCrossRefGoogle Scholar
Tuttle RM, Brokhin M, Omry G et al (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764–770 (RS)PubMedCrossRefGoogle Scholar